Clinical Trials Logo

Tumor, Solid clinical trials

View clinical trials related to Tumor, Solid.

Filter by:

NCT ID: NCT05637034 Recruiting - Tumor, Solid Clinical Trials

68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer

Start date: September 15, 2022
Phase: N/A
Study type: Interventional

To evaluate the potential usefulness of 68Ga-DOTA-F2 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, compared with 18F-FDG PET/CT.

NCT ID: NCT05620134 Recruiting - Cancer Clinical Trials

Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer

Start date: October 17, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced or metastatic cancer.

NCT ID: NCT05432232 Recruiting - Kidney Cancer Clinical Trials

The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy

CAIN
Start date: March 23, 2023
Phase: N/A
Study type: Interventional

The purpose of this trial is to evaluate the technical success and safety profile of the HistoSonics Investigational System for the treatment of primary solid renal tumors.

NCT ID: NCT05378425 Recruiting - Cancer Clinical Trials

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

Start date: September 1, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1,open-label, multi-center, first-in-human, 2-part (Part 1: dose escalation and Part 2: expansion) study, evaluating multiple doses and schedules of intravenously (IV) administered NTX-1088, with or without pembrolizumab, in patients with advanced solid malignancies (i.e., locally advanced or metastatic).

NCT ID: NCT05346276 Recruiting - Tumor, Solid Clinical Trials

PET Imaging of LAG-3 Expression

Start date: April 6, 2022
Phase: N/A
Study type: Interventional

To evaluate the potential usefulness of 68Ga-DOTA-hLAG-3 positron emission tomography/computed tomography (PET/CT) for the evaluation of LAG-3 expression in primary and/or metastatic tumors, compared with histopathological results.

NCT ID: NCT05221320 Recruiting - Clinical trials for Gastrointestinal Cancer

Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies

Start date: May 26, 2022
Phase: Phase 2
Study type: Interventional

This is an open-label, prospective phase two basket trial assessing the efficacy of ulixertinib in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies. All patients enrolled must have a mitogen-activated protein kinase (MAPK) activating mutation to be deemed eligible for trial participation. Each disease-based basket will open to enrollment in two-stages. The opening of stage two will be dependent on the observed responses in the patients enrolled in the first stage.

NCT ID: NCT05103358 Recruiting - Cancer Clinical Trials

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

Start date: February 15, 2022
Phase: Phase 2
Study type: Interventional

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

NCT ID: NCT05094804 Recruiting - Cancer Clinical Trials

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Start date: September 9, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805 administered as a monotherapy and in combination with anti-cancer agents in subjects with advanced solid tumors.

NCT ID: NCT05082610 Recruiting - Cancer Clinical Trials

A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab

Start date: January 1, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1/2, open-label, multi-center, first-in-human, two-stage (Part 1: dose escalation and Part 2: dose expansion) study evaluating multiple doses and schedules of intravenously (IV) administered HMBD-002, with or without pembrolizumab, in patients with advanced solid tumors (i.e., locally advanced and unresectable, or metastatic).

NCT ID: NCT04750772 Recruiting - Colorectal Cancer Clinical Trials

Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer

Start date: October 16, 2019
Phase: N/A
Study type: Interventional

To evaluate the normal physiological distribution of positron nuclide labeled DOTA-FAPI PET/CT in human body and its diagnostic efficiency for colorectal cancers